Our research focus

Human cancers harbour defects in processes that inhibit or enhance tumour growth, so-called tumour suppressor and oncogenes. Importantly, these abnormalities render the tumour cells resistant to many therapies.

Our research is focused on understanding how cancers develop and finding new therapy approaches, including targeted drugs as well as immune therapies to treat these cancers.

We aim to identify novel genes involved in the development of normal and malignant haematopoiesis. We are using in vivo CRISPR approaches to systematically identify new candidate genes, with the ultimate goal of using these targets as novel anti-cancer therapies.

We have recently also started to understand the mechanisms of therapy resistance in cancers and how we can overcome this by reducing the fitness of the cancer cells or enhancing immune therapies using different CRISPR approaches.

Recent publications


Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis

DOI: 10.1038/s41418-023-01145-w

9 March 2023

View abstract
Frontiers Immunology

An arrayed CRISPR screen of primary B cells reveals the essential elements of the antibody secretion pathway

DOI: 10.3389/fimmu.2023.1089243

13 February 2023

View abstract
EMBO Journals

Caspase-8-driven apoptotic and pyroptotic crosstalk causes cell death and IL-1β release in X-linked inhibitor of apoptosis (XIAP) deficiency

DOI: 10.15252/embj.2021110468

17 January 2023

View abstract

Our team

Meet our researchers

  • Prof Marco Herold - Head, Blood Cancer and Immunotherapy Laboratory Publications
  • Andrew Kueh - Platform Lead
  • Emily Lelliott - Postdoctoral Research Fellow